Education
About Us
Working with TipRanks
Follow Us
Akeso, Inc. (HK:9926)
:9926
Ak112
Non-small Cell Lung Cancer
Phase II
Not Yet Recruiting
AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment
Aug 14, 2025
―
Ak112, Ak130
Pancreatic Cancer
Phase II
Not Yet Recruiting
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
Aug 03, 2025
―
Ak104, Ak112, Tt-00420 (Tinengotinib)
Hepatocellular Carcinoma (Hcc)
Phase II
Not Yet Recruiting
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Jun 26, 2025
―
Ebronucimab
Healthy Subjects
Phase I
Not Yet Recruiting
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Healthy Male Chinese Subjects
Jun 20, 2025
―
Ak146d1 For Injection
Advanced Solid Tumors
Phase I
Recruiting
A Study of AK146D1 for Injection in Advanced Solid Tumors
Jun 18, 2025
―
Cadonilimab, Sox Chemotherapy
Gastric And Gastroesophageal Junction (Gej) Adenocarcinoma
Phase III
Not Yet Recruiting
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Jun 10, 2025
―
Ak112
Small Cell Lung Cancer
Phase III
Not Yet Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
May 25, 2025
―
Lenvatinib, Ak104+Lenvatinib
Hepatocellular Carcinoma, Hcc
Phase II
Not Yet Recruiting
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
May 15, 2025
―
Ivonescimab, Ak117, Albumin-Bound Paclitaxel, Gemcitabine
Pancreatic Cancer
Phase III
Not Yet Recruiting
A Phase III Study of Ivonescimab + Chemo With/Without AK117 vs Chemo in Metastatic Pancreatic Cancer
Apr 24, 2025
―
Bevacizumab, Oxaliplatin, Irinotecan, Ak112, Leucovorin And 5-Fu
Colorectal Adenocarcinoma
Phase III
Not Yet Recruiting
A Phase III, Randomized, Controlled and Multi-center Study of AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Apr 23, 2025
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Akeso, Inc. (9926) have in its pipeline
9926 is currently developing the following drugs: Ak112, Ak112, Ak130, Ak104, Ak112, Tt-00420 (Tinengotinib). These drug candidates are in various stages of clinical development as the company works toward FDA approval.